In this episode of The Oncology Journal Club, the team cover one of the most talked-about pancreatic cancer papers of the year, unpacking the promising early results for daraxonrasib in previously treated RAS-mutated pancreatic cancer and the science behind new RAS(ON) therapeutics.
The team also discuss a fascinating phase II study of single-cycle neoadjuvant pembrolizumab in MMR-deficient colon cancer, new recommendations from the Prostate Cancer Working Group 4 and why the terminology we use in prostate cancer matters.
Along the way, there’s discussion of Bob Marley’s acral melanoma, multidisciplinary lung cancer meetings, androgen receptor-positive TNBC, HER2-mutant lung cancer and whether oxybutynin could help men experiencing androgen deprivation-related hot flushes.
You can send us voice notes, connect with us on social media, and physicians can also claim CME points for listening.
